Developing a vaccine to induce broad neutralization against HIV
Exploiting glycan holes and sequence diversity of naturally occurring HIV envelope towards the design of vaccine immunogen panels for induction of neutralization breadth
This study is working on a new vaccine to help your immune system fight HIV by teaching it to recognize and attack the virus better, so it can protect you from getting sick.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11005881 on NIH RePORTER |
What this research studies
This research focuses on creating a vaccine that can stimulate the immune system to produce broadly neutralizing antibodies against HIV. It investigates the unique characteristics of the HIV envelope protein that can be targeted to enhance the immune response. By studying how certain strains of the virus evade the immune system, the researchers aim to design immunogens that can effectively induce a protective response in patients. The approach includes using advanced techniques to analyze the virus's structure and its interaction with antibodies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for HIV infection or those living with HIV who may benefit from enhanced immune responses.
Not a fit: Patients who are not at risk for HIV or those who are already receiving effective antiretroviral therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that provides broad protection against various strains of HIV, significantly improving outcomes for individuals at risk of infection.
How similar studies have performed: Previous research has shown promise in developing vaccines targeting similar mechanisms, indicating potential for success in this novel approach.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Derdeyn, Cynthia Ann — University of Washington
- Study coordinator: Derdeyn, Cynthia Ann
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.